[NEWS] Hua Medicine Enters Research Collaboration Agreement with GemVCare to Generate Real-World Evidence for Dorzagliatin in Hong Kong

July 6, 2026 – Shanghai, China

Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced today that it has entered a scientific research collaboration agreement with GemVCare (referred to as GVC), a Hong Kong-based biotechnology enterprise. Leveraging their respective core strengths, the two parties will conduct joint clinical trial and real-world research using dorzagliatin (trade name: MYHOMSIS®, 華領片®), the Company's global first-in-class glucokinase activator (GKA) and precision diagnostic tools of GVC for the management of Type 2 Diabetes (T2D), This collaboration aims to generate robust clinical evidence to support the drug's local clinical application in Hong Kong.

In February 2026, dorzagliatin received marketing approval from the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China – marking a historic regulatory milestone as the first innovative drug for chronic metabolic disease approved under Hong Kong's "1+" innovative drug mechanism. This approval underscores the Company’s commitment to bringing transformative, first-in-class therapies to patients across Greater China and beyond.

GVC brings singular expertise to this collaboration, encompassing Asia-specific diabetes biobanks, clinical diabetes databases and digital diagnosis and treatment platforms built through 30 years of focus on diabetes data-driven clinical translation for the Asian population. The founders of the firm have proven capabilities in Hong Kong-based clinical trials for regulatory approval, generation of real-world evidence and pharmacoeconomic analysis in diabetes, positioning it as an ideal research enabler for this partnership.

As part of the collaboration, GVC will deploy its professional systems and data infrastructure to support Hua Medicine's aspiration to generate real-world evidence aligned with the requirements of Hong Kong's healthcare system. These evidence will be submitted to the relevant authorities to inform pharmacoeconomic evaluation for supporting its access to a broad population. This collaboration will also demonstrate the capability of Hong Kong as a hub of evidence generation and the value of precision medicine in pursuit of sustainable healthcare and help people live healthier lives.

Dr. Li Chen, Founder and CEO of Hua Medicine, commented: “We are delighted to collaborate with GVC. This partnership will accelerate preparations for the access of dorzagliatin to Hong Kong's healthcare system with coverage. It will also set a replicable benchmark for innovative medicines from China expanding into Hong Kong and Macau through development of localized clinical trials and real-world evidence. Moving forward, the two sides intend to deepen clinical research cooperation in diabetes and unlock the value of precision medicine to benefit more patients with diabetes across the Asia-Pacific region.

About Hua Medicine
Hua Medicine (the "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in patients with type 2 diabetes (T2D), and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult patients with T2D. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral glucose lowering drug that can be used in patients with T2D with renal function impairment.

In February 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China. In June, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of the People's Republic of China.

For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com

About GemVCare
GemVCare was founded in 2014 supported by the Technology Start-up Support Scheme for Universities of the Hong Kong Government Innovation and Technology Commission and based at the Hong Kong Science and Technology Park. It is the first company that combines proprietary algorithms, state-of-the-art molecular techniques and information technology to offer personalized solutions for prevention, classification and treatment of diabetes. Based on three decades of research, our founders used comprehensive databases to define the genetic causes and patterns of diabetes and are amongst the first researchers in the world to discover diabetes gene markers specific for Asian people. GemVCare has successfully licensed and transferred these technologies from The Chinese University of Hong Kong to benefit the community.

For more information
Website: https://www.gemvcare.com/
Email: info@gemvcare.com

Disclaimer
 Nothing in this content constitutes a recommendation, promotion, or medical advice regarding any pharmaceutical product. References to efficacy, safety, or therapeutic potential relate strictly to data presented at the meeting and do not imply regulatory approval for any unapproved indications.